Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
714 ATOR-1017, a 4–1BB antibody, demonstrates promising safety and proof of mechanism in a first-in-human study in patients with advanced solid malignancies
Compose a Response to This Article
Other responses
No responses have been published for this article.